Medtronic PLC banner

Medtronic PLC
NYSE:MDT

Watchlist Manager
Medtronic PLC Logo
Medtronic PLC
NYSE:MDT
Watchlist
Price: 86.28 USD -0.4% Market Closed
Market Cap: $110.8B

EBITDA Margin

27.7%
Current
Declining
by 0.3%
vs 3-y average of 28%

EBITDA Margin shows how much profit a company makes from its core operations before accounting for interest, taxes, and depreciation. It helps assess how efficiently the company runs its main business.

EBITDA Margin
27.7%
=
EBITDA
$9.8B
/
Revenue
$35.5B

EBITDA Margin shows how much profit a company makes from its core operations before accounting for interest, taxes, and depreciation. It helps assess how efficiently the company runs its main business.

EBITDA Margin
27.7%
=
EBITDA
$9.8B
/
Revenue
$35.5B

Peer Comparison

Country Company Market Cap EBITDA
Margin
IE
Medtronic PLC
NYSE:MDT
110.7B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
177.7B USD
Loading...
US
Stryker Corp
NYSE:SYK
127.1B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
92.8B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
47.1B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
44.2B USD
Loading...
US
Zimmer Biomet Holdings Inc
NYSE:ZBH
17.8B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
160.7B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
40.6B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
46B USD
Loading...
US
Resmed Inc
NYSE:RMD
32.8B USD
Loading...

Market Distribution

Higher than 89% of companies in Ireland
Percentile
89th
Based on 313 companies
89th percentile
27.7%
Low
-4 954.1% — 0.2%
Typical Range
0.2% — 18.1%
High
18.1% — 178.8%
Distribution Statistics
Ireland
Min -4 954.1%
30th Percentile 0.2%
Median 13.1%
70th Percentile 18.1%
Max 178.8%

Medtronic PLC
Glance View

In the intricate world of medical technology, Medtronic PLC stands tall as one of the foremost innovators transforming the landscape of healthcare. Founded in 1949 as a humble medical supply repair shop in Minnesota, Medtronic has grown into a global titan, driven by the enduring mission to alleviate pain, restore health, and extend life. The company's breadth is vast, touching nearly every aspect of patient care, from advanced robotic-assisted surgery systems to sophisticated insulin pumps. At its core, Medtronic thrives on relentless research and development, continually bridging the gap between cutting-edge technology and practical medical solutions. By forging deep alliances with healthcare providers and systems around the globe, the company ensures its innovations are not only groundbreaking but also widely accessible. The company's financial engine purrs to life primarily through the development and sale of medical devices across four major segments: Cardiac and Vascular Group, Minimally Invasive Therapies, Restorative Therapies Group, and Diabetes Group. Each unit meticulously focuses on innovating and providing solutions relevant to its field, ensuring a diversified portfolio with robust pipelines. For instance, within the Cardiac and Vascular Group, Medtronic supplies life-saving products like pacemakers and stents while also exploring breakthrough therapies such as transcatheter heart valves. By capitalizing on a global presence, the company strategically taps into both mature markets in North America and Europe and emerging markets across Asia and Latin America, thereby driving substantial revenue streams. Through this multifaceted operational framework, Medtronic not only sustains its market dominance but also reinvests in the future of medical technology, symbolizing a perpetual cycle of growth and innovation.

MDT Intrinsic Value
96.86 USD
Undervaluation 11%
Intrinsic Value
Price $86.28
What is EBITDA Margin?
EBITDA Margin shows how much profit a company makes from its core operations before accounting for interest, taxes, and depreciation. It helps assess how efficiently the company runs its main business.
How is EBITDA Margin calculated?

EBITDA Margin is calculated by dividing the EBITDA by the Revenue.

EBITDA Margin
27.7%
=
EBITDA
$9.8B
/
Revenue
$35.5B
What is Medtronic PLC's current EBITDA Margin?

The current EBITDA Margin for Medtronic PLC is 27.7%, which is below its 3-year median of 28%.

How has EBITDA Margin changed over time?

Over the last 3 years, Medtronic PLC’s EBITDA Margin has decreased from 28.5% to 27.7%. During this period, it reached a low of 26.9% on Jul 26, 2024 and a high of 29% on Jul 28, 2023.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett